Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Consolidated Net Income (2020 - 2025)

Foghorn Therapeutics has reported Consolidated Net Income over the past 6 years, most recently at -$22.2 million for Q4 2025.

  • Quarterly results put Consolidated Net Income at -$22.2 million for Q4 2025, down 13.65% from a year ago — trailing twelve months through Dec 2025 was -$77.6 million (up 10.36% YoY), and the annual figure for FY2025 was -$77.6 million, up 10.36%.
  • Consolidated Net Income for Q4 2025 was -$22.2 million at Foghorn Therapeutics, down from -$16.5 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for FHTX hit a ceiling of -$14.3 million in Q3 2023 and a floor of -$30.5 million in Q1 2023.
  • Median Consolidated Net Income over the past 5 years was -$23.9 million (2021), compared with a mean of -$23.7 million.
  • Biggest five-year swings in Consolidated Net Income: plummeted 68.9% in 2021 and later skyrocketed 44.33% in 2023.
  • Foghorn Therapeutics' Consolidated Net Income stood at -$28.5 million in 2021, then dropped by 1.33% to -$28.9 million in 2022, then increased by 16.55% to -$24.1 million in 2023, then grew by 19.09% to -$19.5 million in 2024, then fell by 13.65% to -$22.2 million in 2025.
  • The last three reported values for Consolidated Net Income were -$22.2 million (Q4 2025), -$16.5 million (Q3 2025), and -$18.8 million (Q2 2025) per Business Quant data.